Metabolism Assays Market worth $2.1 billion by 2028
The Metabolism Assays Market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=135163479
Global Metabolism Assays Dynamics
DRIVER: Increasing funding and investments in metabolic research
Metabolic research funding and investments are crucial for advancing the metabolic processes understanding, producing new metabolic disease treatments, and improving public health. Diseases like diabetes, obesity, lipid metabolism, mitochondrial disorders, and metabolic pathways are being considered as metabolic diseases. Various sources, including government agencies, private foundations, pharmaceutical companies, and academic institutions are the sources for funding.
RESTRAINTS: High cost of metabolism assay analyzers
The adoption of metabolism assays can be hindered due to the high costs, especially with limited budgeted facilities like smaller research laboratories or healthcare facilities. To mitigate these costs, the organizations may explore options like group purchasing, leasing or financing agreements, and collaborations with larger institutions. There is the development of more cost-effective analyzers or alternative testing methods that reduce expenses while maintaining accuracy and reliability, as technology advances and competition increases. For instance, the Seahorse Xfe 96 Cell Analyzer System and Seahorse XF HS Mini Analyzer by Agilent Technologies, Inc. (US) cost USD 189,612 and USD 68,611, respectively.
OPPORTUNITY: Integration with wearable devices
The overall health monitoring and management experience for individuals can be enhanced by integrating metabolism assay data with digital health platforms, apps, and wearable devices. For instance, Sweat-based wearable technologies have great potential to collect important data on biomarkers which are related to metabolic syndrome and its associated diseases. These wearable devices can measure glucose, CRP, cortisol, and sodium levels, making them invaluable for patients at risk of developing diabetes and cardiovascular diseases.
CHALLENGE: Complexity of assay development
Due to the intricate nature of metabolic pathways and the need for precise measurement techniques, it can be complex and time-consuming to develop accurate and reliable metabolism assays. Ensuring consistency and reproducibility across different experiments and laboratories can be a challenge. A multidisciplinary approach is required for these complexities which involves expertise in biochemistry, cell biology, molecular biology, analytical chemistry, and computational biology.
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=135163479
“In 2022, assay kits & reagents segment to observe the highest growth rate of the metabolism assays market, by product.”
Based on product, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share can be attributed to features like availability and integration with other technologies like wearable devices.
“In 2022, colorimetry segment to dominate the metabolism assays market, by technology.”
Based on technology, the metabolism assays market is segmented into colorimetry, fluorimetry, and spectrometry. The colorimetry segment accounted for the largest share of the metabolism assays market in 2022. Also, this segment is estimated to witness the highest growth during the forecast period. The large share is due to well-established method for measuring metabolites and biomarkers in a wide range of biological samples and large use in industrial settings to assess metabolic parameters and provide valuable data for various applications, including disease diagnosis and drug development.
“In 2022, North America to dominate in metabolism assays market.”
The global metabolism assays market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to dominate during the forecast period, primarily due to the sedentary work life which will lead to obesity & diabetes, and large population consuming junk food causing obesity. However, during the forecast period, Asia Pacific is expected to register highest CAGR. The factors contributing to the growth of Asia Pacific are large patient pool, growing number of local players, increasing awareness, and rise in disease research fundings by the government.
Key Market Players
Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan)
Recent Developments:
- In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.
- In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision’s product portfolio and create value through portfolio expansion and leveraging Abcam’s global channels to market.
- In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent’s range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.
Report Objectives
- To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To define, describe, segment, and forecast the metabolism assays market by product, technology, application, end-user, and region
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall metabolism assay market
- To forecast the size of the metabolism assays market in five main regions along with their respective key countries, namely, North America, Europe, the Asia Pacific, Rest of the world.
- To profile key players in the metabolism assays market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments, such as acquisitions; product launches; expansions; collaborations, agreements, & partnerships; and R&D activities of the leading players in the metabolism assays market.
- To benchmark players within the metabolism assays market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Report Link: (Metabolism Assays Market)
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/metabolism-assays-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/metabolism-assays.asp
Comments
Post a Comment